He Jie said, at present, the individual differences of cancer patients are very obvious, the treatment is also very complex, based on the current relatively limited medical evidence developed by the diagnosis and treatment of **** knowledge, guidelines, and even standards, is not quite able to keep up with the development of medicine. The development of medicine is an exploratory science, and many standards, including international practice, are several years old, but the current situation has evolved, so the indications for medicines approved or the medical programs written into guidelines are probably outdated, and patients should be given treatments that are beyond the indications, or beyond the guidelines, based on more adequate clinical evidence, and also for the purpose of exploring the effectiveness of diagnosis and treatment. There are a lot of drugs that do work beyond the indications.
Hejie emphasized that clinical pharmacology institutions and ethics committees should strictly monitor that these clinical studies of over-indications and over-guidelines are innovations in clinical care, not over-treatment, but are implemented under strict monitoring. "It has also been proven that many cancer patients can benefit in such cases." Hergé stated.